The prognostic value of reactive stroma on prostate needle biopsy: A population-based study

Prostate

Volumn 75, Issue 6, 2015, Pages 662-671

  Sæter, Thorstein ^a   Vlatkovic, Ljiljana ^b   Waaler, Gudmund ^a   Servoll, Einar ^a   Nesland, Jahn M ^b,c   Axcrona, Karol ^d,e   Axcrona, Ulrika ^b  

^a Sørlandet Hospital   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

biopsy; mortality; prognosis; prostate cancer; reactive stroma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REACTIVE STROMAL GRADING; STROMA; SURVIVAL RATE; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATE TUMOR;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84925654029     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22957     Document Type: Article

References (26)

1. Martin NE, Depinho RA,. Prognostic determinants in prostate cancer. Cancer J 2011; 17: 429-437.
2. Taylor RA, Risbridger GP,. Prostatic tumor stroma: A key player in cancer progression. Curr Cancer Drug Targets 2008; 8: 490-497.
3. Barron DA, Rowley DR,. The reactive stroma microenvironment and cancer progression. Endocr Relat Cancer 2012; 19: 187-204.
4. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR,. Reactive stroma in prostate cancer: Induction of myofibroblasts phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8: 2912-2923.
5. Dvorak HF,. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
6. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
7. Tuxhorn JA, Ayala GE, Rowley DR,. Reactive stroma in prostate cancer progression. J Urol 2001; 166: 2472-2483.
8. Franco OE, Shaw AK, Strand DW, Hayward SW,. Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 2010; 21: 33-39.
9. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR,. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003; 9: 4792-4801.
10. Yanagisawa N, Rile L, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE,. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stroma grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 2007; 28: 1611-1620.
11. Ayala GE, Bahar M, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M, Ittmann MM, Kadmon D, Miles BJ, Wheeler TM, Rowley DR,. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol 2011; 178: 79-87.
12. Billis A, Meirelles L, Freitas LLL, Polidro AS, Fernandes HA, Padilha MM, Magna LA, Reis LO, Ferreira U,. Adenocarcinoma on needle prostatic biopsies: Does reactive stroma predicts biochemical recurrence in patients following radical prostatectomy? Int Braz J Urol 2013; 39: 320-327.
13. Waaler G, Ludvigsen TC,. Prostatic cancer in Aust-Agder County, Norway. Scand J Urol Nephrol 1991; 25: 107-110.
14. Waaler G, Ludvigsen TC, Stenwig AE,. Prognosis of incidental prostatic cancer in Aust-Agder County, Norway. Eur Urol 1990; 18: 179-183.
15. Waaler G, Stenwig AE,. Prognosis of localised prostatic cancer managed by "wait and watch" policy. Br J Urol 1993; 72: 214-219.
16. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M,. Mechanisms of bone metastasis in prostate cancer: Clinical implications. Best Prac Res Clin Endocrinol Metab 2008; 22: 341-355.
17. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M,. Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171: 1513-1519.
18. Rana A, Karamanis K, Lucas MG, Chrisholm GD,. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 1992; 69: 277-281.
19. Ohori M, Wheeler TN, Scardino PT,. The new American joint committee on cancer and international union against cancer. TNM classification of prostate cancer. Cancer 1994; 74: 104-114.
20. Epstein JI, Allsbrook JC, Amin MB, Egevad LL,. ISUP grading committee. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostate carcinoma. Am J Surg Pathol 2005; 29: 1228-1241.
21. Dignam JJ, Zhang Q, Kocherginsky MN,. The use and interpretion of competing risks regression models. Clin Cancer Res 2012; 18: 2301-2308.
22. Grobbee DE, Hoes AW,. Clinical epidemiology. Principles, Methods and applications for clinical research, 2nd edition. Burlington: Jones & Bartlett Learning 2014; pp. 135.
23. Caso JR, Mouraviev V, Tsivian M,. Prostate cancer: An evolving paradigm. J Endourol 2010; 24: 805-809.
24. Nair B, Wilt T, MacDonald R, Rutks I,. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic Reviews 2002; Article CD003506.
25. Grobbee DE, Hoes AW,. Clinical epidemiology. Principles, Methods and applications for clinical research, 2nd ed. Burlington: Jones & Bartlett Learning 2014; pp. 138.
26. Elabbady AA, Khedr MM,. Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score. Eur Urol 2006; 49: 49-53.